Showing 4751-4760 of 5646 results for "".
- Nicox Announces Senior Management Changehttps://modernod.com/news/nicox-announces-senior-management-change/2478295/Nicox announced that Tomas Navratil, PhD, Executive Vice President & Head of Research & Development of the Nicox Group and General Manager of Nicox Ophthalmics, will be leaving the company on October 16, 2020 to pursue other opportunities. Nicox has initiated a search for a successor. In
- Ophthalmic Societies Call on FDA to Keep Moxifloxacin on Bulk Substance Listhttps://modernod.com/news/ophthalmic-societies-call-on-fda-to-keep-moxifloxacin-on-bulk-substance-list/2478293/Several ophthalmic organizations have collectively sent a letter to the FDA requesting that the agency retain moxifloxacin as Category 1 for outsourcing facility use (503b), citing a demonstrated clinical need for the medication as a bulk substance. The request comes after the FDA, on July 31, ga
- MetLife to Acquire Versant Health, Owner of Davis Vision and Superior Visionhttps://modernod.com/news/metlife-to-acquire-versant-health-owner-of-davis-vision-and-superior-vision/2478292/MetLife announced it has entered into a definitive agreement to acquire Versant Health from an investor group led by Centerbridge Partners and including FFL Partners for approximately $1.675 billion in an all-cash transaction. Versant Health owns the marketplace brands Davis Vision and Superior V
- Oxford Says AstraZeneca Trial Illnesses May Not Be Linked to COVID-19 Vaccinehttps://modernod.com/news/oxford-says-astrazeneca-trial-illnesses-may-not-be-linked-to-covid-19-vaccine/2478290/Neurological symptoms developed by some volunteers in a trial testing AstraZeneca’s COVID-19 vaccine candidate AZD1222 either probably did not come about as a result of the vaccine, or there is not enough evidence to say one way or the other, according to the University of Oxford. The discl
- Santen Acquires Eyevance Pharmaceuticalhttps://modernod.com/news/santen-acquires-eyevance-pharmaceutical/2478289/In a move to enter the US pharmaceuticals market and expand its global presence, Santen announced it has acquired Eyevance Pharmaceutical for $225 million in cash. In the deal, Santen Holdings U.S. Inc., a wholly-owned subsidiary of Santen, will acquire all of the outstanding shares of Ey
- Facebook and EssilorLuxottica Announce Collaboration for Smart Glasseshttps://modernod.com/news/facebook-and-essilorluxottica-announce-collaboration-for-smart-glasses/2478288/Facebook and EssilorLuxottica announced a multiyear collaboration to develop the next generation of smart glasses. The announcement was made by Mark Zuckerberg during Facebook Connect, an annual conference held virtually from California. Terms of the deal were not disclosed. The par
- BVI Introduces Patient Packs Aimed at Helping US Ophthalmologists Bring Patients Backhttps://modernod.com/news/bvi-introduces-patient-packs-aimed-at-helping-us-ophthalmologists-bring-patients-back/2478280/BVI has released a line of Patient Packs to help US ophthalmologists bring patients back to the office and OR with confidence, according to a company news release. Ophthalmologists are seeking to get back to normal and address the backlog of patients whose vision has been negatively impact
- 5 Reasons Why Medical Meetings Will Never Be the Samehttps://modernod.com/news/5-reasons-why-medical-meetings-will-never-be-the-same/2478276/In the wake of the COVID-19 pandemic, the virtual medical meeting is now the norm. And while it’s admirable that key data are being disseminated (often for free), there is no escaping the fact that it is a fundamentally different and lesser experience, according to commentary
- Researchers Are Able to Visualize the Retina’s Function at the Cellular Levelhttps://modernod.com/news/researchers-are-able-to-visualize-the-retinas-function-at-the-cellular-level/2478271/While there is no cure for blindness and macular degeneration, scientists have accelerated the process to find a cure by visualizing the inner workings of th
- AstraZeneca Must Explain Spinal Ailment to Resume Vaccine Trialhttps://modernod.com/news/astrazeneca-must-explain-spinal-ailment-to-resume-vaccine-trial/2478268/A day after pausing its COVID-19 vaccine trials due to a possible serious neurological problem in one patient, AstraZeneca faced numerous questions about what exactly caused the issue and whether it could be related to the vaccine, according to a Bloomberg News